Phase 4 N=99 A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval
Pain
Primary: Median of Cumulative Pain Scores Up to 60 Minutes Post Procedure — 2; 2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=80 Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty
Postoperative Pain Following Knee Arthroplasty
Primary: Hours Until Discharge Readiness — 61; 55 hours
Phase 4 N=100 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Acne Vulgaris
Primary: Number of Participants With Adverse Events (AE) — 5; 16 Participants
Phase 4 N=40 Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
Autism Spectrum Disorders
Primary: Change From Baseline in Brain Activity During Task (Task-based fMRI) After a Single Dose of Nasal Spray — 0.11; -0.26; -0.15; -0.16 Change-from-baseline (BOLD response)
Phase 4 N=728 A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Weighted Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 0-24 Hours at Week 12 for Modified Per Protocol (mPP) Population — 0.045; 0.030…
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 4 N=28 Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects
Endothelial Dysfunction
Primary: Percent Change in Flow Mediated Dilation — 12.3; 11.6; 10.9; 11.1 percent change
Phase 4 N=182 Weight Loss With Exenatide Treatment
Obesity
Primary: Change in Body Weight — 6.5; 7.5 percentage weight loss — p=<0.05
Phase 4 N=732 A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Weighted Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 0-24 Hours at Week 12 for Modified Per Protocol (mPP) Population — 0.039; 0.029…
Phase 4 N=117 The Impact of Omega Three Fatty Acids on Vascular Function in HIV
High Triglyceride Level · HIV Infection
Primary: Triglyceride Level — 130; 159 mg/dL
Phase 4 N=5 Improving Sleep Quality in Heart Failure
Sleep Disturbance · Heart Failure
Primary: Sleep Latency — -73.3; 21.9 minutes
Phase 4 N=103 Determine the Clinical Advantage of IV vs PO Acetaminophen
Inguinal Hernia
Primary: PACU Visual Analogue Pain Scores — 2.13; 1.52; 2.88; 2.41 score on a scale
Phase 4 N=40 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery
Spine Surgery
Primary: Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade — 3.9; 26.29 Minutes
Phase 4 N=89 Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial
Sinusitis
Primary: Sinonasal Outcome Test - 22 — 31.3; 31.0 score on a scale
Phase 4 N=210 A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis
Psoriasis Vulgaris
Primary: Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 — 85; 40 Participants — p=<0.001